Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Malignant Pleural Mesothelioma Overview 8
Therapeutics Development 9
Pipeline Products for Malignant Pleural Mesothelioma - Overview 9
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis 10
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies 11
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes 13
Malignant Pleural Mesothelioma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Malignant Pleural Mesothelioma - Products under Development by Companies 17
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes 20
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development 21
Advantagene, Inc. 21
Amphera BV 22
AnGes MG, Inc. 23
ArQule, Inc. 24
Bayer AG 25
Biogen Inc 26
Bionomics Limited 27
Biotecnol Limited 28
Boehringer Ingelheim GmbH 29
Boston Biomedical, Inc. 30
Bristol-Myers Squibb Company 31
CanBas Co., Ltd. 32
Concordia International Corp 33
Eli Lilly and Company 34
EnGeneIC Ltd 35
F. Hoffmann-La Roche Ltd. 36
Genelux Corporation 37
GlaxoSmithKline Plc 38
Juno Therapeutics Inc. 39
MedImmune LLC 40
Merck & Co., Inc. 41
Millennium Pharmaceuticals Inc 42
MolMed S.p.A. 43
Morphotek, Inc. 44
Novartis AG 45
Ono Pharmaceutical Co., Ltd. 46
Oxford BioMedica Plc 47
Pharma Mar, S.A. 48
Polaris Pharmaceuticals, Inc. 49
Sellas Inc 50
Targovax ASA 51
VasGene Therapeutics, Inc. 52
Verastem, Inc. 53
Virttu Biologics Limited 54
Vyriad Inc 55
Malignant Pleural Mesothelioma - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 61
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
alisertib - Drug Profile 68
amatuximab - Drug Profile 74
anetumab ravtansine - Drug Profile 76
bevacizumab - Drug Profile 79
BG-00001 - Drug Profile 88
BMS-986148 - Drug Profile 89
BNC-105 - Drug Profile 90
CBP-501 - Drug Profile 95
Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 97
Cellular Immunotherapy to Target Mesothelin for Oncology - Drug Profile 98
Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile 99
CSG-MESO - Drug Profile 100
defactinib hydrochloride - Drug Profile 101
durvalumab - Drug Profile 108
durvalumab + tremelimumab - Drug Profile 119
galinpepimut-S - Drug Profile 123
ganetespib - Drug Profile 126
GEN-0101 - Drug Profile 138
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 140
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 141
GLONC-1 - Drug Profile 142
GSK-2256098 - Drug Profile 146
HSV-1716 - Drug Profile 148
iCasp9M28z - Drug Profile 151
JTCR-016 - Drug Profile 152
LY-3023414 - Drug Profile 154
MesoCancerVac - Drug Profile 156
MesoCART - Drug Profile 157
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 158
MTG-201 - Drug Profile 160
napabucasin - Drug Profile 162
NGR-hTNF - Drug Profile 169
nintedanib - Drug Profile 175
nivolumab - Drug Profile 184
Oncolytic Virus for Malignant Pleural Mesothelioma - Drug Profile 218
Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma - Drug Profile 219
ONCOS-102 - Drug Profile 220
OXB-301 - Drug Profile 223
pegargiminase - Drug Profile 226
pembrolizumab - Drug Profile 233
porfimer sodium - Drug Profile 266
rAd-IFN - Drug Profile 268
S-588210 - Drug Profile 270
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 271
TargomiRs - Drug Profile 272
TB-535 - Drug Profile 274
tivantinib - Drug Profile 275
trabectedin - Drug Profile 280
Vas-01 - Drug Profile 287
VS-5584 - Drug Profile 289
Malignant Pleural Mesothelioma - Dormant Projects 292
Malignant Pleural Mesothelioma - Discontinued Products 293
Malignant Pleural Mesothelioma - Product Development Milestones 294
Featured News & Press Releases 294
Appendix 310
Methodology 310
Coverage 310
Secondary Research 310
Primary Research 310
Expert Panel Validation 310
Contact Us 310
Disclaimer 311

List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016 13
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H2 2016 25
Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H2 2016 26
Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H2 2016 27
Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H2 2016 28
Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H2 2016 29
Malignant Pleural Mesothelioma - Pipeline by Biogen Inc, H2 2016 30
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H2 2016 31
Malignant Pleural Mesothelioma - Pipeline by Biotecnol Limited, H2 2016 32
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 33
Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2016 34
Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2016 35
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2016 36
Malignant Pleural Mesothelioma - Pipeline by Concordia International Corp, H2 2016 37
Malignant Pleural Mesothelioma - Pipeline by Eli Lilly and Company, H2 2016 38
Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2016 39
Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 40
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H2 2016 41
Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2016 42
Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2016 43
Malignant Pleural Mesothelioma - Pipeline by MedImmune LLC, H2 2016 44
Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H2 2016 45
Malignant Pleural Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 46
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H2 2016 47
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H2 2016 48
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H2 2016 49
Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 50
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2016 51
Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2016 52
Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 53
Malignant Pleural Mesothelioma - Pipeline by Sellas Inc, H2 2016 54
Malignant Pleural Mesothelioma - Pipeline by Targovax ASA, H2 2016 55
Malignant Pleural Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H2 2016 56
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H2 2016 57
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2016 58
Malignant Pleural Mesothelioma - Pipeline by Vyriad Inc, H2 2016 59
Assessment by Monotherapy Products, H2 2016 60
Assessment by Combination Products, H2 2016 61
Number of Products by Stage and Target, H2 2016 63
Number of Products by Stage and Mechanism of Action, H2 2016 66
Number of Products by Stage and Route of Administration, H2 2016 69
Number of Products by Stage and Molecule Type, H2 2016 71
Malignant Pleural Mesothelioma - Dormant Projects, H2 2016 296
Malignant Pleural Mesothelioma - Discontinued Products, H2 2016 297

List of Figures
Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016 13
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Assessment by Monotherapy Products, H2 2016 60
Number of Products by Top 10 Targets, H2 2016 62
Number of Products by Stage and Top 10 Targets, H2 2016 62
Number of Products by Top 10 Mechanism of Actions, H2 2016 65
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 65
Number of Products by Top 10 Routes of Administration, H2 2016 68
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 68
Number of Products by Top 10 Molecule Types, H2 2016 70
Number of Products by Stage and Top 10 Molecule Types, H2 2016 70